Canadabis Capital Inc. Reveals Strategic Direction for 2020

Published: February 12, 2020

Canadabis Capital Inc. Reveals Strategic Direction for 2020

CanadaBis Capital Inc. , a holder of a federal licence to cultivate, process and sell cannabis under the Cannabis Act, has announced its strategic direction and facility expansion focus for its subsidiary 1998643 AB LTD. (“Stigma Grow”). Their facility in Red Deer Alberta acts as the Company’s cornerstone; providing the craft-quality plants needed to supply for all four pillars of their integrated business model.

“We are advantageously positioned to grow and manufacture products that will be among the highest quality and potency in the market,” said President & CEO, Travis McIntyre. “Stigma Grow intends to leverage the ability our own, top-quality flower, state-of-the-art technology, and the insight provided by our skilled and experienced staff, to target consumers and partner LPs that are looking for high-quality, “bud-run” extract product variations.”

Stigma Extracts

The Company anticipates a shift in consumer behaviour from a focus on dry flower to a focus on concentrates in 2020 and beyond. To prepare for this demand, the Company has spent six months perfecting their systems and constructing a CIDI Lab to house hydrocarbon extraction processing — positioning them to bring difficult-to-produce products to market on a mass scale.

In addition to representing products that are in high demand, Stigma concentrate products will be some of the first available in the Canadian legal market.

Stigma’s concentrates promise an extremely clean, consistent and pure form of cannabis product, and Stigma’s third-party processing abilities have already captured the interest of several LPs looking for service providers capable of facilitating the expansion of their own lines of products.

Travis explains, “With the current CIDI Lab constructed and our expansion plans well underway, we are perfectly positioned to take on a large volume of toll processing for other LPs. We see this as an opportunity for those who have flower who would like to expand their offerings to address evolved demands of a growing market.”

At present, Stigma has signed agreements with several reputable LPs to conduct concentrate manufacturing on their behalf, and currently hold POs for provincial channels scheduled for a late-March delivery of high-quality, terpene-rich, shatter, badder, live res badder and live res caviar. The Company is currently in talks for more partnerships and expect to make another announcement in the coming weeks.

Indoor Cultivation

Although the Company sees a shift in focus from flower to concentrates, they have not lost sight of the need to provide high-quality craft cannabis, and recognize the synergistic connection.

As with any Premium Product the best inputs generate the best outputs. The combination of the two sets the stage for our long-term plans as a craft-cannabis cultivator recognized for high-quality in everything we produce. This ongoing commitment to both sides of the cannabis market will allow us to control the quality of our products, and always ensure an optimized offering.

Stigma Grow currently operates 22,000 sq/ft of production space and is in the midst of their Phase 2 expansion which will increase this area to 66,000 sq/ft by mid-2020. Proudly offering craft-quality products with optimal cannabinoid profiles, Stigma Grow is the first Health Canada-licensed producer operating in the Red Deer area.

Cannabis Root-Infusion

Stigma Roots seeks to bring the healing potential of cannabis roots to a market seeking alternative treatment options from a wide range of ailments.  Unlike the leaves and buds of the cannabis plant, which are strictly regulated, the roots of the cannabis plant do not fall under the same, strict regulations; providing a valuable opportunity to extend Stigma’s products and brand messaging to the general public.

By using the roots of a cannabis plant as the primary ingredient in their lotions and balms, Stigma Roots offers three advantages: (1)products capable of providing the relief and benefits people seek; (2) a profit stream generated from roots that would typically be wasted; and, (3) a way to reach an entirely new audience with our message — one that may not typically engage with a recreational cannabis brand.

INDICAtive Collection

The Company owns and operates a standalone retail location in Red Deer Alberta’s Gasoline Alley — INDICAtive Collection. In addition to providing polish and professionalism, INDICAtive Collection acts as a touch point for a company focused on providing that which is currently lacking.

Far more than a pillar acting in and of itself, INDICAtive Collection provides our cultivation and processing R&D departments with first-hand statistical evidence of what sells, what’s trending and what is not widely accepted by the public. Not only does this first-hand research help guide our retail inventory, it also guides our efforts at the LP level; ensuring we are producing products that will be in high-demand.

Recent News

View All News Items

Latest Article

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

The legalization of cannabis edibles, extracts and topicals will expand the cannabis market and create new opportunities for producers, innovators and investors. According to a recent report from Deloitte, the Canadian market for these new cannabis products is expected to be worth $2.7 billion annually, with edibles accounting for more than half ($1.6 billion).


Read Article